BiotechTube

Nalmefene hydrochloride

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alcohol Dependence

Conditions

Alcohol Dependence

Trial Timeline

Jul 13, 2015 → Jan 18, 2017

NCT ID
NCT02382276

About Nalmefene hydrochloride

Nalmefene hydrochloride is a phase 3 stage product being developed by Lundbeck for Alcohol Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT02382276. Target conditions include Alcohol Dependence.

What happened to similar drugs?

11 of 20 similar drugs in Alcohol Dependence were approved

Approved (11) Terminated (2) Active (8)
✅Seroquel XRAstraZenecaApproved
✅Acamprosate or NaltrexoneMerckApproved
✅Acamprosate + PlaceboMerckApproved
✅LevetiracetamUCBApproved
✅losartan (drug)LundbeckApproved
✅Selincro® 18 mg with continuous psychosocial support: Cohort ALundbeckApproved
✅nalmefeneLundbeckApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02382276Phase 3Completed

Competing Products

20 competing products in Alcohol Dependence

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
LanifibranorInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
LY686017 + PlaceboEli LillyPhase 2
35
LY3537031 + PlaceboEli LillyPhase 3
47
AD04 (ondansetron) + Matching placeboAdial PharmaceuticalsPhase 3
30
GODEX + PlaceboCelltrionPhase 3
47
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
ASP8062 + PlaceboAstellas PharmaPhase 2
35
LY686017 + PlaceboEli LillyPhase 2
35
Mazdutide + PlaceboEli LillyPhase 2
42
opioid receptor kappa antagonistEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
35
LY2196044 + placeboEli LillyPhase 2
35